- $9.09bn
- $8.90bn
- $42.28m
U.S. RESEARCH ROUNDUP- Constellation Brands, Merck, WD-40
Brief: Verona Pharma Expects $400 Mln In Cash & Cash Equivalents As Of Dec 31, 2024
U.S. STOCKS ON THE MOVE-Tempus AI, AeroVironment, Gold miners
U.S. STOCKS ON THE MOVE-Verona Pharma, McCormick, gold miners
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month (updated)
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month
Verona Pharma's US shares rise on FDA nod for chronic lung disease therapy
US FDA approves Verona Pharma's therapy for 'smoker's lungs' (updated)
FDA approves Verona Pharma's therapy for 'smoker's lungs'
Brief: Verona Pharma Enters Into Debt Facility Of Up To $400 Million With Oxford Finance And Hercules Capital
Brief: Verona Pharma Announces US FDA Accepted NDA Filing For Ensifentrine For Maintenance Treatment Of COPD
Verona Pharma gains as USFDA to review lung disease therapy
Brief: Verona Pharma Says US FDA Has Accepted New Drug Application Filing For Ensifentrine For Maintenance Treatment Of COPD
Brief: Verona Pharma Says NDA Submission On Schedule For Q2 2023
Verona Pharma up after Regeneron's drug shows promise in lung disease study
Verona surges as brokerages raise PT after positive drug trial results
Verona Pharma gains as lung disease therapy meets main goal in late-stage study
U.S. STOCKS ON THE MOVE-Verona Pharma, Tesla, Otonomy Inc
Verona surges as lung disease therapy meets main goal in late-stage study